FDA
-
-
-
-
-
-
-
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
-
-
-
-
-
-
-
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
-
-
-
-
-
-
-
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
-
-
-
-
-
-
-
Adagene partners with Incyte for cancer drug combination study
-
-
-
-
-
-
-
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
-
-
-
-
-
-
-
Registration Momentum Builds Across the Oncology Pipeline
-
-
-
-
-
-
-
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
-
323,121 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

